与当代乳腺癌治疗相关的心力衰竭
1Megan Durkin and Neisha DeJesus practice in cardio-oncology at Memorial Sloan Kettering Cancer Center in New York, N.Y. The authors have disclosed no potential conflicts of interest, financial or otherwise.
概括
接受 antracyclines 和 anti-HER2 治疗的乳腺癌患者面临心脏毒性风险. 早期的心脏监测和风险评估对于在治疗期间管理和预防心力衰竭至关重要.
科学领域:
- 在瘤学瘤学.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 乳腺癌的治疗方法,如人环素和抗HER2疗法,可能会导致心脏毒性.
- 化疗引起的心力衰竭 (CIHF) 管理指南仍在发展.
- 识别有风险的患者是优化护理的关键.
研究的目的:
- 审查正在接受特定治疗的乳腺癌患者心脏毒性风险因素和预测因素.
- 强调心脏监测和风险评估策略的重要性.
- 为了突出进一步研究管理左心室功能障碍的需要.
主要方法:
- 对与环素和抗HER2药物相关的心脏毒性的文献综述.
- 对心脏毒性风险因素和临床预测因素的分析.
- 讨论当前的监测和管理建议.
主要成果:
- 心脏毒性是乳腺癌患者用多克索鲁比和特拉斯图祖马布治疗的重大问题.
- 治疗前心声学和心血管风险因素评估可以预测左心室功能障碍.
- 在整个治疗过程中,建议对心脏进行密切监测.
结论:
- 危险患者的早期识别和警的心脏监测至关重要.
- 优化治疗策略需要进一步的临床试验来管理心脏毒性.
- 需要多学科的方法来改善患者的治疗结果.
相关概念视频
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
424
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
424
Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
Heart Failure Drugs: Diuretics
370
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370
Ischemic Heart Disease: Overview
1.3K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.3K


